Cell and Gene Therapies.jpg
Cell & Gene Therapy
|
Matt Hewitt

Cell and Gene Therapies: What's Hot in 2022

Allogeneic cell therapies are rapidly gaining interest in the field, while manufacturing of autologous therapies are becoming streamlined

What's Hot in 2022: Cell and Gene TherapiesWe’ve now seen multiple CAR (chimeric antigen receptor) T-cell products reach the market. They have all been autologous therapies which involve re-engineering a patient’s own T cells to seek out and kill cancerous cells. Coming of age, however, is a new breed of CAR-T cell therapies which rely on manufacturing multiple therapeutic doses from universal donors. These allogeneic therapies are gaining interest in the field because they potentially provide a way to scale up cell therapy manufacturing and produce many therapeutic doses per manufacturing run. In principle this method should significantly reduce therapeutic costs providing increased patient access to potentially curative therapies. A recent report surveying 500 industry leaders (conducted by CRB’s Horizons) examined how the balance between autologous versus allogeneic cell therapy development is evolving. The current open, labor-intensive manufacturing practices required for autologous therapies makes these individualized therapies difficult to scale and meet the therapeutic demand of large patient populations. As allogeneic therapy development has gained speed, it’s likely the first commercially approved allogeneic product will come onto the market in the next 12-24 months—a seminal milestone for allogeneic therapies.

Although it’s likely commercial allogeneic therapies are coming, autologous therapies are continue to be developed with streamlined manufacturing. Next year we expect to see significant progress in lowering manufacturing costs due to programs migrating to closed, automated manufacturing platforms. The migration to these closed, automated platforms is already accelerating and it’s expected to continue. In moving to a closed, automate manufacturing platform, manufacturing costs may drop by 30-40%, increasing patient access to autologous therapies.

- Matt Hewitt, Executive Director, Scientific Services Cell & Gene Therapy, Charles River 

Our What's Hot series are annual forecasts provided by Charles River's thought leaders. Check out here what our scientists are predicting for 2022 and what they called out in years past.